In an AMP Global presentation, Danish Cancer Society Research Center scientists used the test to study urine samples from individuals who developed bladder cancer up to 15 years later.
Groups from Austria, Spain, Germany, and the US demonstrated that the GeneReader can reliably detect cancer mutations in tissue and liquid biopsy samples.
Eleven laboratories that are part of Thermo's OncoNetwork Consortium tested the Oncomine Lung cfDNA assay on reference samples.
The groups said they hope their recommendations lead to higher-quality sequencing results in the lab and better care for cancer patients in the clinic.
The guidance includes recommendations for extended RAS mutation testing to guide anti-EGFR therapy, as well as updated endorsements for analysis of mismatch repair status.
The recommendations were developed by a working group of the AMP Clinical Practice Committee that included representatives from ACMG, ASCO, and CAP.
According to multiple sources in Washington, DC, the FDA has been informing stakeholders in policy circles of the decision.
In a new AMP working group project, labs can volunteer to compare their interpretation of challenging variants to help identify where and how the guidelines might be improved.
The US Supreme Court decision cleared the way for large-scale sequencing or drove prices to unsustainable levels, depending on your opinion.
A hospital study demonstrated an average total cost saving of around $25,000 for each patient with candidemia.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.